Analytical Data
-
基因名
IPO13
- Application
-
别名
IMP13; KAP13; RANBP13; Karyopherin-13; Ran-binding protein 13
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O94829
-
表达区间
Gly14~Phe202
-
分子量
25kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IPO13 (Importin 13) is a member of the importin family, which plays a critical role in the nuclear transport of proteins and RNA molecules. It is particularly involved in the transport of larger proteins, including transcription factors and other nuclear proteins, across the nuclear envelope. Understanding the functionality and mechanisms of IPO13 is essential due to its implications in various biological processes, such as gene regulation, cell signaling, and the overall maintenance of cellular homeostasis. Dysregulation of nuclear transport can lead to several diseases, including cancer and neurodegenerative disorders. Recent studies have focused on characterizing the structural and functional aspects of IPO13, examining its interaction with cargo proteins and other importins, as well as its regulatory mechanisms. The exploration of IPO13 could provide insights into therapeutic targets for diseases associated with impaired nuclear transport. Additionally, the development of recombinant IPO13 proteins for further experimental applications could enhance our understanding of nucleocytoplasmic transport dynamics and their influence on cellular functions. Thus, IPO13 represents a vital area of research with potential implications in cell biology, disease mechanisms, and therapeutic innovations.
